Amino Acid, Peptide, or Protein – Page 57

BioNTech, Regeneron, mRNA immunotherapy, BNT111, Phase 2 trial, melanoma, cancer treatment, PD-1 checkpoint inhibitor, cemiplimab, FixVac platform, uridine mRNA-LPX technology

BioNTech and Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma

9 months ago talkbio0Tagged BioNTech, cemiplimab, Libtayo, melanoma, mRNA cancer, Phase 2 Clinical Trials, Regeneron, Tetravalent RNA-lipoplex Cancer Vaccine BNT111, Vaccines

BioNTech, Regeneron, mRNA cancer vaccine, Phase II trial, melanoma, BNT111, cemiplimab, Libtayo

NewAmsterdam’s Obicetrapib Hits Primary Endpoint in Phase III HeFH Study, but Falls Short of Expectations

9 months ago talkbio0Tagged Cardiovascular Diseases, CETP protein, human, Familial hypercholesterolemia - heterozygous, Heterozygote, High Density Lipoprotein Cholesterol, Hypercholesterolemia, Familial, Inhibitor, LDL Cholesterol Lipoproteins, NewAmsterdam Pharma, Obicetrapib, Phase 3 Clinical Trials

NewAmsterdam Pharma, Obicetrapib, CETP Inhibitor, Phase III Trial, Heterozygous Familial Hypercholesterolemia (HeFH), LDL Cholesterol, HDL Cholesterol, Cardiovascular Disease

NICE Rejects AstraZeneca’s Enhertu for Breast Cancer Treatment Due to Pricing Concerns

9 months ago talkbio0Tagged AstraZeneca, Enhertu, Malignant neoplasm of breast, Nitroglycerin/Sodium Citrate/Ethanol Solution, Pricing, Rejection (Psychology)

NICE, AstraZeneca, Enhertu, Breast Cancer, Pricing, Rejection

GSK Partners with Flagship Pioneering to Develop 10 Novel Medicines and Vaccines

9 months ago talkbio0Tagged bioplatform companies, Drug Discovery, Flagship, Immunology, Partnership, Pfizer, Pioneering, Respiration Disorders, RNA, Messenger, SmithKline Beecham, Vaccines

GSK, Flagship Pioneering, drug discovery, vaccines, respiratory disease, immunology, bioplatform companies, mRNA vaccines, Pfizer, biotech partnership

AstraZeneca and Daiichi Sankyo’s Enhertu Denied NICE Recommendation for NHS Use, Prompting Calls for Review Process Reform

9 months ago talkbio0Tagged AstraZeneca, Cost Effectiveness, Daiichi, Enhertu, Malignant neoplasm of breast, Nance-Horan syndrome, Nitroglycerin/Sodium Citrate/Ethanol Solution, Review Process Reform, Sankyo

Enhertu, NICE, AstraZeneca, Daiichi Sankyo, NHS, breast cancer treatment, cost-effectiveness, pricing dispute, review process reform